List of Excipients in Branded Drug TRAMADOL HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Trigen Laboratories LLC	TRAMADOL HYDROCHLORIDE	tramadol hydrochloride	13811-689	CELLULOSE, MICROCRYSTALLINE
Trigen Laboratories LLC	TRAMADOL HYDROCHLORIDE	tramadol hydrochloride	13811-689	ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER
Trigen Laboratories LLC	TRAMADOL HYDROCHLORIDE	tramadol hydrochloride	13811-689	FD&C BLUE NO. 2
Trigen Laboratories LLC	TRAMADOL HYDROCHLORIDE	tramadol hydrochloride	13811-689	GELATIN

Generic Drugs Containing TRAMADOL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	tramadol hydrochloride	0093-0058	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	tramadol hydrochloride	0093-0058	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	tramadol hydrochloride	0093-0058	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	tramadol hydrochloride	0093-0058	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in TRAMADOL HYDROCHLORIDE?

# Of NDCs	Excipient
29	AMMONIA
1	AMMONIUM LAURETH-5 SULFATE
64	ANHYDROUS LACTOSE
23	BUTYL ALCOHOL

Excipient Strategy and Commercial Opportunities for Tramadol Hydrochloride

Last updated: February 25, 2026

What Are the Key Excipients for Tramadol Hydrochloride Formulations?

Tramadol hydrochloride formulations typically contain excipients that optimize stability, bioavailability, and patient acceptability. Common excipients include:

• Binders: Microcrystalline cellulose improves tablet cohesion.
• Disintegrants: Sodium starch glycolate facilitates tablet breakup.
• Fillers: Lactose monohydrate enhances bulk.
• Lubricants: Magnesium stearate reduces tablet sticking.
• Coatings: Hydroxypropyl methylcellulose (HPMC) offers controlled release.

The choice depends on the formulation type (immediate-release, extended-release) and route of administration.

How Does Excipient Selection Influence Formulation Performance?

Excipients impact absorption rates, stability, manufacturing efficiency, and patient compliance:

• Bioavailability: Binders and disintegrants affect dissolution and onset of action.
• Stability: Protect against moisture and oxidation, extending shelf-life.
• Manufacturing: Lubricants prevent sticking, ensuring smooth production.
• Patient Experience: Coatings can mask bitterness or enable controlled release.

Selected excipients should meet pharmacopoeial standards, be compatible with tramadol, and minimize potential for adverse reactions.

What Are the Market Trends in Excipient Development for Pain Medications?

The market shows increasing focus on:

• Enhanced bioavailability: Use of nanotechnology and solubilizers.
• Controlled release systems: Osmotic pumps and matrix systems.
• Patient-centric formulations: Orally disintegrating tablets, patches.
• Sustainability: Eco-friendly excipients developed for greener manufacturing.

Major players invest in proprietary excipients to differentiate formulations and improve therapeutic profiles.

What Are Commercial Opportunities for Excipient Suppliers and Innovators?

Opportunities arise in several areas:

• Novel excipients: Developing excipients that enable faster manufacturing or improved stability.
• Specialized formulations: Creating excipients tailored for extended-release tramadol.
• Partnerships: Collaborations with pharmaceutical companies to develop branded formulations.
• Regulatory advantages: Processing excipients with established safety profiles streamline approval pathways.

Limited patent protections on excipients can lead to market saturation; innovation remains key for differentiation.

How Do Regulatory Considerations Affect Excipient Strategy?

Regulatory agencies (FDA, EMA) require:

• GRAS status or approved use in pharmaceuticals.
• Optimal specifications that do not compromise safety or efficacy.
• Compatibility data supporting excipient-drug interactions.

Developers must ensure excipient compliance to expedite approval processes and reduce delays.

What Are the Key Challenges in Excipient Development and Commercialization?

• Compatibility: Ensuring excipients do not alter tramadol’s stability or activity.
• Supply chain: Securing reliable raw material sources.
• Cost: Balancing excipient quality with manufacturing expenses.
• Regulatory hurdles: Navigating differing international standards.

Investing in robust characterization methods and establishing strategic supply agreements mitigate these challenges.

Which Formulation Types Present the Most Opportunities?

• Immediate-release tablets: Largest segment, requiring cost-effective excipients.
• Extended-release formulations: Growing market, demanding specialized excipients for sustained delivery.
• Transdermal patches: Emerging, with excipients that facilitate permeation and skin compatibility.

Innovation in controlled-release and alternative delivery systems offers significant commercial gains.

Key Takeaways

• Excipient selection directly impacts tramadol hydrochloride’s stability, bioavailability, and patient compliance.
• Market drivers include enhanced bioavailability, controlled release, and patient-friendly formats.
• Opportunities are centered around novel excipients, proprietary formulations, and regulatory navigation.
• Compatibility, supply security, cost, and regulatory compliance remain critical challenges.
• Focused development in extended-release and transdermal formulations aligns with market growth.

FAQs

1. How do excipients influence tramadol’s absorption?
Excipients like disintegrants and solubilizers accelerate dissolution, enhancing absorption and onset of action.

2. Are there patented excipients specific for tramadol formulations?
No; most excipients are generic. Innovation involves developing proprietary formulations or delivery systems.

3. What is the role of excipients in extended-release tramadol products?
They control drug release kinetics, sustain plasma levels, and improve dosing convenience.

4. How does regulatory status impact excipient choice?
Regulatory agencies require excipients to have established safety profiles, which influences selection and formulation approval timeframes.

5. What are emerging excipient technologies in pain medication delivery?
Nanosponges, biodegradable polymers, and stimuli-responsive excipients are being explored for improved delivery systems.

---

References

[1] U.S. Food and Drug Administration. (2022). Inactive Ingredients in Approved Drug Products.
[2] European Medicines Agency. (2020). Guidelines on excipients in medicines for human use.
[3] Desai, P., & Patel, R. (2019). Role of oral excipients in drug formulation. Journal of Pharmaceutical Sciences, 108(2), 507–514.
[4] Singh, S., et al. (2021). Advances in controlled-release formulations of analgesics. International Journal of Pharmaceutics, 595, 120181.